Posted: 19 April 2023
Patrys Limited, a therapeutic antibody development company, is pleased to announce that the US Patent and Trademark Organisation has granted two patents that provide further intellectual property protection for Patrys’ deoxymab antibody technology until 2039.
The two patents that have been granted by the US PTO are:
- US patent number: 11,613,590, titles “Blinding proteins 1” which provides coverage until September 2039; and
- US patent number: 11,590,242, titled “Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors” which provides coverage until January 2039.
The composition of matter patents provides robust intellectual property protection around the deoxymabs themselves, including variants thereof, as well as their use for therapeutic applications. This patent, co-filed with Yale University, is the first US patent to be granted specifically for PAT-DX1 and PAT-DX3, the humanized forms of the original 3E10 antibody.
The second patent covers the combination of deoxymabs with nanocarriers that simultaneously cause DNA damage or inhibit the repair of damaged DNA to potentially provide a powerful new approach for treating cancer. There are now five granted patents covering the use of conjugated deoxymabs that provide opportunities for both internal development programs and partnering opportunities for Patrys.
